Phase I study of the Aurora B kinase inhibitor barasertib (AZD1152) to assess the pharmacokinetics, metabolism and excretion in patients with acute myeloid leukemia

PURPOSE: Barasertib (AZD1152) is a pro-drug that rapidly undergoes phosphatase-mediated cleavage in serum to release barasertib-hQPA, a selective Aurora B kinase inhibitor that has shown preliminary activity in clinical studies of patients with acute myeloid leukemia (AML). The pharmacokinetic (PK),...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Dennis, Mike, Davies, Michelle, Oliver, Stuart, D’Souza, Roy, Pike, Laura, Stockman, Paul
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Springer-Verlag 2012
Gaiak:
Original Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3428523/
https://ncbi.nlm.nih.gov/pubmed/22864876
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-012-1939-2
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak